Adicet Bio (NASDAQ:ACET – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports.
ACET has been the subject of several other research reports. Guggenheim assumed coverage on shares of Adicet Bio in a research note on Monday, September 30th. They issued a “buy” rating and a $7.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Adicet Bio in a research report on Friday, September 20th. StockNews.com raised shares of Adicet Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, October 8th. Finally, Canaccord Genuity Group cut their price target on Adicet Bio from $19.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.50.
View Our Latest Stock Analysis on ACET
Adicet Bio Price Performance
Adicet Bio (NASDAQ:ACET – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.03. As a group, research analysts expect that Adicet Bio will post -1.41 EPS for the current fiscal year.
Institutional Investors Weigh In On Adicet Bio
Institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Adicet Bio in the 1st quarter valued at $28,000. Price T Rowe Associates Inc. MD acquired a new position in Adicet Bio in the first quarter valued at $37,000. Point72 DIFC Ltd grew its position in Adicet Bio by 77.5% during the second quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after acquiring an additional 14,596 shares during the period. Marshall Wace LLP acquired a new stake in Adicet Bio during the second quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Adicet Bio during the second quarter worth about $62,000. 83.89% of the stock is currently owned by hedge funds and other institutional investors.
Adicet Bio Company Profile
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Featured Stories
- Five stocks we like better than Adicet Bio
- What are earnings reports?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.